Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer

View/Open
221719_1_merged_1562017078.pdf (3.538Mb)
Publication date
11/2019
Author
Metadata
Show full item record
Citation
Ponnusamy , S , He , Y , Hwang , D-J , Thiyagarajan , T , Houtman , R , Bocharova , V , Sumpter , B G , Fernandez , E , Johnson , D , Du , Z , Pfeffer , L M , Getzenberg , R H , McEwan , I J , Miller , D D & Narayanan , R 2019 , ' Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer ' , Clinical Cancer Research , vol. 25 , no. 22 , pp. 6764-6780 . https://doi.org/10.1158/1078-0432.CCR-19-1458
URI
https://hdl.handle.net/2164/15067
DOI
https://doi.org/10.1158/1078-0432.CCR-19-1458
Rights
This manuscript has been accepted for publication in Clinical Cancer Research, which is published by the American Association for Cancer Research.
Collections